Amneal Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Deficiency
| Class A Common Stock · AdditionalPaid-in Capital · Stockholders’Accumulated Deficit · AccumulatedOtherComprehensive Loss · Non-Controlling Interests · Total Deficiency · Redeemable Non-Controlling Interests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2025 | 314,565 | $3,146 | $571,794 | $(535,005) | $(110,729) | $(535) | $(71,329) | $77,292 |
| Net income (loss) | — | — | — | 62,256 | — | (23) | 62,233 | 15,767 |
| Foreign currency translation adjustments | — | — | — | — | (8,830) | — | (8,830) | — |
| Stock-based compensation | — | — | 8,816 | — | — | — | 8,816 | — |
| Exercise of stock options | 14 | — | 38 | — | — | — | 38 | — |
| Restricted stock unit vesting, net of shares withheld to cover payroll taxes | 4,419 | 44 | (44,349) | — | — | — | (44,305) | — |
| Unrealized gain on cash flow hedge, net of tax of $0 | — | — | — | — | 4,394 | — | 4,394 | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (7,147) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | 2,878 | — | 2,878 | — |
| Other, net of tax of $0 | — | — | — | — | 136 | — | 136 | — |
| Balance at March 31, 2026 | 318,998 | $3,190 | $536,299 | $(472,749) | $(112,151) | $(558) | $(45,969) | $85,912 |
| Class A CommonStock · AdditionalPaid-in Capital · Stockholders’Accumulated Deficit · AccumulatedOtherComprehensive Loss · Non-Controlling Interests · Total Deficiency · Redeemable Non-Controlling Interests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2024 | 309,881 | $3,099 | $560,206 | $(607,062) | $(65,510) | $(245) | $(109,512) | $64,974 |
| Net income (loss) | — | — | — | 12,195 | — | (88) | 12,107 | 12,511 |
| Foreign currency translation adjustments | — | — | — | — | (1,632) | — | (1,632) | — |
| Stock-based compensation | — | — | 7,258 | — | — | — | 7,258 | — |
| Exercise of stock options | 25 | — | 69 | — | — | — | 69 | — |
| Restricted stock unit vesting, net of shares withheld to cover payroll taxes | 3,479 | 35 | (21,727) | — | — | — | (21,692) | — |
| Unrealized loss on cash flow hedge, net of tax of $0 | — | — | — | — | (12,154) | — | (12,154) | — |
| Tax distributions, net | — | — | — | — | — | — | — | (4,874) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | (6,444) | — | (6,444) | — |
| Balance at March 31, 2025 | 313,385 | $3,134 | $545,806 | $(594,867) | $(85,740) | $(333) | $(132,000) | $72,611 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.